Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.

Exelixis (NASDAQ:EXEL – Get Free Report) was downgraded by equities researchers at StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Tuesday. A number of other equities ...

with the FDA in RET-positive non-small cell lung cancer in early April. It then filed for approval in the two thyroid cancer indications – RET mutant medullary thyroid cancer and RET fusion ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Two new studies represent a big step toward developing innovative molecular therapies capable of disrupting the ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

Doug Kellogg, professor of molecular, cell, and developmental biology at UC Santa Cruz, has been awarded $2.95 million from ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research.

The main risk factors for tonsil cancer are smoking, drinking alcohol and infection with the human papilloma virus (HPV). Most tonsil cancers are a type called squamous cell carcinoma. A small number ...